Published in J Nucl Med on November 01, 2011
In vivo molecular imaging of chemokine receptor CXCR4 expression in patients with advanced multiple myeloma. EMBO Mol Med (2015) 1.83
Prospective of ⁶⁸Ga-radiopharmaceutical development. Theranostics (2013) 1.32
Disclosing the CXCR4 expression in lymphoproliferative diseases by targeted molecular imaging. Theranostics (2015) 1.11
Molecular imaging of chemokine receptor CXCR4. Theranostics (2013) 1.04
(68)Ga-Pentixafor-PET/CT for Imaging of Chemokine Receptor 4 Expression in Glioblastoma. Theranostics (2016) 0.88
Differential expression and prognostic value of the chemokine receptor CXCR4 in bronchopulmonary neuroendocrine neoplasms. Oncotarget (2015) 0.87
Bridged cyclams as imaging agents for chemokine receptor 4 (CXCR4). Nucl Med Biol (2014) 0.86
Multimodality imaging of CXCR4 in cancer: current status towards clinical translation. Curr Mol Med (2013) 0.84
Evaluation of (68)Ga- and (177)Lu-DOTA-PEG4-LLP2A for VLA-4-Targeted PET Imaging and Treatment of Metastatic Melanoma. Mol Pharm (2015) 0.82
Structural characterization and in vivo evaluation of β-Hairpin peptidomimetics as specific CXCR4 imaging agents. Mol Pharm (2015) 0.81
Differential somatostatin and CXCR4 chemokine receptor expression in MALT-type lymphoma of gastric and extragastric origin. J Cancer Res Clin Oncol (2016) 0.78
Biomarkers in preclinical cancer imaging. Eur J Nucl Med Mol Imaging (2015) 0.78
Prospective Study of (68)Ga-NOTA-NFB: Radiation Dosimetry in Healthy Volunteers and First Application in Glioma Patients. Theranostics (2015) 0.78
The influence of different metal-chelate conjugates of pentixafor on the CXCR4 affinity. EJNMMI Res (2016) 0.77
Radiopharmaceuticals as probes to characterize tumour tissue. Eur J Nucl Med Mol Imaging (2015) 0.76
In vivo imaging of therapy-induced anti-cancer immune responses in humans. Cell Mol Life Sci (2012) 0.76
Design, synthesis and in vitro characterization of fluorescent and paramagnetic CXCR4-targeted imaging agents. Am J Nucl Med Mol Imaging (2013) 0.76
Response assessment with the CXCR4-directed positron emission tomography tracer [(68)Ga]Pentixafor in a patient with extranodal marginal zone lymphoma of the orbital cavities. EJNMMI Res (2017) 0.75
Targeted positron emission tomography imaging of CXCR4 expression in patients with acute myeloid leukemia. Haematologica (2016) 0.75
Stroma targeting nuclear imaging and radiopharmaceuticals. Int J Mol Imaging (2012) 0.75
FDG-PET imaging in hematological malignancies. Blood Rev (2016) 0.75
Preclinical evaluation of [(68)Ga]NOTA-pentixafor for PET imaging of CXCR4 expression in vivo - a comparison to [(68)Ga]pentixafor. EJNMMI Res (2016) 0.75
Al[(18)F]NOTA-T140 Peptide for Noninvasive Visualization of CXCR4 Expression. Mol Imaging Biol (2016) 0.75
Synthesis and evaluation of an (18)F-labeled pyrimidine-pyridine amine for targeting CXCR4 receptors in gliomas. Nucl Med Biol (2016) 0.75
Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma. J Clin Oncol (2007) 6.65
RGD modified polymers: biomaterials for stimulated cell adhesion and beyond. Biomaterials (2003) 5.34
Activation of integrin function by nanopatterned adhesive interfaces. Chemphyschem (2004) 4.66
PET to assess early metabolic response and to guide treatment of adenocarcinoma of the oesophagogastric junction: the MUNICON phase II trial. Lancet Oncol (2007) 4.03
The conserved Bardet-Biedl syndrome proteins assemble a coat that traffics membrane proteins to cilia. Cell (2010) 3.83
Stem cell mobilization by granulocyte colony-stimulating factor in patients with acute myocardial infarction: a randomized controlled trial. JAMA (2006) 3.78
Mechanical reperfusion in patients with acute myocardial infarction presenting more than 12 hours from symptom onset: a randomized controlled trial. JAMA (2005) 3.67
Monocytes, neutrophils, and platelets cooperate to initiate and propagate venous thrombosis in mice in vivo. J Exp Med (2012) 3.63
Cell spreading and focal adhesion dynamics are regulated by spacing of integrin ligands. Biophys J (2007) 3.57
Cerebral metabolic changes accompanying conversion of mild cognitive impairment into Alzheimer's disease: a PET follow-up study. Eur J Nucl Med Mol Imaging (2003) 3.50
Noninvasive visualization of the activated alphavbeta3 integrin in cancer patients by positron emission tomography and [18F]Galacto-RGD. PLoS Med (2005) 3.12
Performance measurements of the Siemens mMR integrated whole-body PET/MR scanner. J Nucl Med (2011) 2.98
First clinical experience with integrated whole-body PET/MR: comparison to PET/CT in patients with oncologic diagnoses. J Nucl Med (2012) 2.76
MEDSYNDIKATE--a natural language system for the extraction of medical information from findings reports. Int J Med Inform (2002) 2.70
A randomized trial of coronary stenting versus balloon angioplasty as a rescue intervention after failed thrombolysis in patients with acute myocardial infarction. J Am Coll Cardiol (2004) 2.67
Tissue classification as a potential approach for attenuation correction in whole-body PET/MRI: evaluation with PET/CT data. J Nucl Med (2009) 2.65
Association of ST-elevation and non-ST-elevation presentation on ECG with transmurality and size of myocardial infarction as assessed by contrast-enhanced magnetic resonance imaging. J Electrocardiol (2013) 2.64
Prediction of response to neoadjuvant chemotherapy by sequential F-18-fluorodeoxyglucose positron emission tomography in patients with advanced-stage ovarian cancer. J Clin Oncol (2005) 2.54
CXCR4 regulates interneuron migration in the developing neocortex. J Neurosci (2003) 2.44
Assessment of myocardial viability with contrast-enhanced magnetic resonance imaging: comparison with positron emission tomography. Circulation (2002) 2.43
Regulation of μ-opioid receptors: desensitization, phosphorylation, internalization, and tolerance. Pharmacol Rev (2013) 2.42
Tumor targeting with radiolabeled alpha(v)beta(3) integrin binding peptides in a nude mouse model. Cancer Res (2002) 2.38
Receptor endocytosis counteracts the development of opioid tolerance. Mol Pharmacol (2004) 2.36
Positron emission tomography in non-small-cell lung cancer: prediction of response to chemotherapy by quantitative assessment of glucose use. J Clin Oncol (2003) 2.35
SPECT/CT. J Nucl Med (2008) 2.34
Metabolic imaging predicts response, survival, and recurrence in adenocarcinomas of the esophagogastric junction. J Clin Oncol (2006) 2.31
Internalization of sst2, sst3, and sst5 receptors: effects of somatostatin agonists and antagonists. J Nucl Med (2006) 2.23
Prediction of tumor response by FDG-PET: comparison of the accuracy of single and sequential studies in patients with adenocarcinomas of the esophagogastric junction. Eur J Nucl Med Mol Imaging (2007) 2.23
Time course of tumor metabolic activity during chemoradiotherapy of esophageal squamous cell carcinoma and response to treatment. J Clin Oncol (2004) 2.22
Intratumoral spatial distribution of hypoxia and angiogenesis assessed by 18F-FAZA and 125I-Gluco-RGD autoradiography. J Nucl Med (2008) 2.22
[18F]Galacto-RGD: synthesis, radiolabeling, metabolic stability, and radiation dose estimates. Bioconjug Chem (2004) 2.20
Two-step methodology for high-yield routine radiohalogenation of peptides: (18)F-labeled RGD and octreotide analogs. J Nucl Med (2004) 2.14
First demonstration of 3-D lymphatic mapping in breast cancer using freehand SPECT. Eur J Nucl Med Mol Imaging (2010) 2.07
Effect of the A118G polymorphism on binding affinity, potency and agonist-mediated endocytosis, desensitization, and resensitization of the human mu-opioid receptor. J Neurochem (2004) 2.07
Prediction of individual clinical outcome in MCI by means of genetic assessment and (18)F-FDG PET. J Nucl Med (2005) 2.05
N-methylation of peptides: a new perspective in medicinal chemistry. Acc Chem Res (2008) 2.02
Therapy-dependent influence of time-to-treatment interval on myocardial salvage in patients with acute myocardial infarction treated with coronary artery stenting or thrombolysis. Circulation (2003) 1.97
Positron emission tomography using [18F]Galacto-RGD identifies the level of integrin alpha(v)beta3 expression in man. Clin Cancer Res (2006) 1.96
Positron detection for the intraoperative localisation of cancer deposits. Eur J Nucl Med Mol Imaging (2007) 1.95
Perspectives on NMR in drug discovery: a technique comes of age. Nat Rev Drug Discov (2008) 1.95
Biodistribution and pharmacokinetics of the alphavbeta3-selective tracer 18F-galacto-RGD in cancer patients. J Nucl Med (2005) 1.94
WT p53, but not tumor-derived mutants, bind to Bcl2 via the DNA binding domain and induce mitochondrial permeabilization. J Biol Chem (2006) 1.94
Lateral spacing of integrin ligands influences cell spreading and focal adhesion assembly. Eur J Cell Biol (2005) 1.93
TNFR1 signaling and IFN-gamma signaling determine whether T cells induce tumor dormancy or promote multistage carcinogenesis. Cancer Cell (2008) 1.91
18F-labeled galacto and PEGylated RGD dimers for PET imaging of αvβ3 integrin expression. Mol Imaging Biol (2009) 1.90
An unfolded CH1 domain controls the assembly and secretion of IgG antibodies. Mol Cell (2009) 1.90
FDG PET imaging of locally advanced gastric carcinomas: correlation with endoscopic and histopathological findings. Eur J Nucl Med Mol Imaging (2002) 1.87
Cilengitide: the first anti-angiogenic small molecule drug candidate design, synthesis and clinical evaluation. Anticancer Agents Med Chem (2010) 1.87
Beta amyloid in Alzheimer's disease: increased deposition in brain is reflected in reduced concentration in cerebrospinal fluid. Biol Psychiatry (2009) 1.85
Hypoxia-specific tumor imaging with 18F-fluoroazomycin arabinoside. J Nucl Med (2005) 1.85
Prediction of response to preoperative chemotherapy in gastric carcinoma by metabolic imaging: results of a prospective trial. J Clin Oncol (2003) 1.84
Myeloperoxidase attracts neutrophils by physical forces. Blood (2010) 1.84
The RGD motif in fibronectin is essential for development but dispensable for fibril assembly. J Cell Biol (2007) 1.81
Hepatitis C treatment in "difficult-to-treat" psychiatric patients with pegylated interferon-alpha and ribavirin: response and psychiatric side effects. Hepatology (2007) 1.79
Central poststroke pain and reduced opioid receptor binding within pain processing circuitries: a [11C]diprenorphine PET study. Pain (2004) 1.77
Cxcr7 controls neuronal migration by regulating chemokine responsiveness. Neuron (2011) 1.76
ERG status is unrelated to PSA recurrence in radically operated prostate cancer in the absence of antihormonal therapy. Clin Cancer Res (2011) 1.75
Expression of CEACAM1 in adenocarcinoma of the lung: a factor of independent prognostic significance. J Clin Oncol (2002) 1.75
Impact of order and disorder in RGD nanopatterns on cell adhesion. Nano Lett (2009) 1.75
Evolution of left ventricular ejection fraction and its relationship to infarct size after acute myocardial infarction. J Am Coll Cardiol (2007) 1.69
Multimeric cyclic RGD peptides as potential tools for tumor targeting: solid-phase peptide synthesis and chemoselective oxime ligation. Chemistry (2003) 1.69
Abciximab in patients with acute ST-segment-elevation myocardial infarction undergoing primary percutaneous coronary intervention after clopidogrel loading: a randomized double-blind trial. Circulation (2009) 1.69
Simplified quantification of myocardial flow reserve with flurpiridaz F 18: validation with microspheres in a pig model. J Nucl Med (2011) 1.67
Reirradiation of recurrent high-grade gliomas using amino acid PET (SPECT)/CT/MRI image fusion to determine gross tumor volume for stereotactic fractionated radiotherapy. Int J Radiat Oncol Biol Phys (2005) 1.66
Asymmetric activation of the hsp90 dimer by its cochaperone aha1. Mol Cell (2010) 1.65
A conserved spider silk domain acts as a molecular switch that controls fibre assembly. Nature (2010) 1.65
Trifunctional somatostatin-based derivatives designed for targeted radiotherapy using auger electron emitters. J Nucl Med (2005) 1.64
Evaluation of a novel (18)F-labeled positron-emission tomography perfusion tracer for the assessment of myocardial infarct size in rats. Circ Cardiovasc Imaging (2009) 1.64
Selective pressure-regulated retroinfusion of fibroblast growth factor-2 into the coronary vein enhances regional myocardial blood flow and function in pigs with chronic myocardial ischemia. J Am Coll Cardiol (2003) 1.62
The N-terminal domain of p53 is natively unfolded. J Mol Biol (2003) 1.62
CXCR4 expression increases liver and lung metastasis in a mouse model of pancreatic cancer. Gastroenterology (2005) 1.61
Ligands for mapping alphavbeta3-integrin expression in vivo. Acc Chem Res (2009) 1.60
Radiolabeled tracers for imaging of tumor angiogenesis and evaluation of anti-angiogenic therapies. Curr Pharm Des (2004) 1.59
Impact of local versus global ligand density on cellular adhesion. Nano Lett (2011) 1.58
CEACAM1+ myeloid cells control angiogenesis in inflammation. Blood (2009) 1.57
Imaging of integrin alphavbeta3 expression. Cancer Metastasis Rev (2008) 1.56
Ecology, inhibitory activity, and morphogenesis of a marine antagonistic bacterium belonging to the Roseobacter clade. Appl Environ Microbiol (2005) 1.56
Induction chemotherapy in Barrett cancer: influence on surgical risk and outcome. Ann Surg (2007) 1.56
Discovery of complex mixtures of novel long-chain quorum sensing signals in free-living and host-associated marine alphaproteobacteria. Chembiochem (2005) 1.56
Comparison of a monomeric and dimeric radiolabeled RGD-peptide for tumor targeting. Cancer Biother Radiopharm (2002) 1.55
Heterodimerization of somatostatin and opioid receptors cross-modulates phosphorylation, internalization, and desensitization. J Biol Chem (2002) 1.54
Value of a Dixon-based MR/PET attenuation correction sequence for the localization and evaluation of PET-positive lesions. Eur J Nucl Med Mol Imaging (2011) 1.54
Imaging of amyloid plaques and cerebral glucose metabolism in semantic dementia and Alzheimer's disease. Neuroimage (2007) 1.53